
Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

Your AI-Trained Oncology Knowledge Connection!


Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses a phase II trial of umbralisib in chronic lymphocytic leukemia.

Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia.

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

Published: June 25th 2018 | Updated:

Published: June 17th 2018 | Updated:

Published: December 13th 2011 | Updated: